Showing results (321-330 of 701) with videos related to

Sort By:
Pageof 71
ACS Omega|November 17, 2025
Hemp-Derived Hierarchical Porous Carbon with an Optimized Pore Structure by NaOH Activation for Supercapacitor ApplicationsKhemjiranee Bowornthommatadsana, Kanisorn Klangvijit, Teerayut Uwanno, et al.
Endocrinologia Japonica|August 1, 1988
Reduction in urine C-peptide clearance rate after metabolic control in NIDDM patientsS D Hsieh, Y Iwamoto, A Matsuda, et al.
Bioorganic & Medicinal Chemistry Letters|April 8, 2017
Divergent synthesis of kinase inhibitor derivatives, leading to discovery of selective Gck inhibitorsTakanori Matsumaru, Makoto Inai, Kana Ishigami, et al.
Annals of Hematology|December 18, 2024
Angioimmunoblastic T-cell lymphoma harboring a t(8;14)(q24;q11.2)/TCR::MYC translocation that presented with intestinal infiltrationSatoshi Ichikawa, Hiroki Kato, Naoya Morota, et al.
International Journal of Hematology|December 28, 2022
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignanciesWataru Munakata, Kiyoshi Ando, Masahiro Yokoyama, et al.
The American Journal of Surgical Pathology|April 7, 2025
High FCGR2B Expression Can Identify Low-tumor-burden Follicular Lymphoma Patients Who Do Not Require Any Antilymphoma Therapy for a Long TermShotaro Watanabe, Hiroki Kato, Tohru Fujiwara, et al.
Cancer Science|March 1, 2019
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in JapanWataru Munakata, Kiyoshi Ando, Kiyohiko Hatake, et al.
Leukemia & Lymphoma|July 2, 2024
Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 studyJun Takizawa, Takanori Teshima, Daisuke Ennishi, et al.
Investigative Ophthalmology & Visual Science|May 11, 1999
Corneal wound healing in tenascin knockout mouseA Matsuda, A Yoshiki, Y Tagawa, et al.
Pageof 71